In 2022, the number of financing events and total financing in the global pharmaceutical and health field will remain at a high level and show a growing trend
.
For example, in the near future, a large number of pharmaceutical companies have successively announced the completion of financing
of 100 billion yuan.
On Oct.
7, oncology company Nested Therapeutics announced the completion of a $90 million Series A funding round, which will advance Nested's total funding to $125 million to help develop
its next generation of cancer precision medicine drugs.
Specifically, the funding Nested receives will enable the company to advance its R&D projects, attract more talented people, and further develop its cancer-driven mutation platform to expand the field of
precision medicine.
Nested's platform consists of three major projects: mapping mutant populations to corresponding structural proteomes, identifying drug-making "pockets" and their cancer-driving mechanisms, and designing innovative drugs optimized for drug-making "pockets
.
"
On Oct.
4, clinical-stage biotech company Vergent Bioscience announced the completion of a $21.
5 million Series B round, led by Orlando Health Ventures, with new investors Intuitive Surgical, Inc.
, Windham Venture Partners and Rex Health Ventures, as well as existing investor Spring Mountain Capital and Colle Capital followed
.
It is worth mentioning that the Series B financing has brought Vergent's total funding to date to $34 million
.
On the same day, drug discovery company Cellarity also announced the completion of a $121 million Series C round of financing, bringing its total funding to date to $274 million
.
Investors in this round include Flagship Pioneering and Series B investors, as well as new investors Kyowa Kirin Co.
Ltd.
and Hanwha Impact Partners
.
The proceeds of the financing will be used to develop Cellarity's talent base, strengthen the company's platform, and bring its pipeline to the clinic
.
Prior to this, American biotech company RayzeBio has also announced the completion of a $160 million Series D financing
.
It is understood that since the beginning of operations in August 2020, RayzeBio has been committed to advancing the development of radiopharmaceuticals, which has also launched multiple rounds of financing, plus this financing, RayzeBio has received $418 million in financing
in more than two years since its establishment.
From the above, biotechnology companies are the focus
of capital attention.
In fact, in addition to multinational pharmaceutical companies, China's biomedical and medical fields are also rising financing tide
.
Incomplete statistics show that there were 73 early financing events in China's medical and health sector in Q3 of 2022, with a financing amount of 4.
7 billion yuan.
In addition, CGT is a subdivision of Q3 in the biomedical field, according to statistics, there are 8 CGT companies that have completed early financing in Q3, accounting for nearly 22%.
Industry analysis believes that this is mainly the current, China's medicine, medical field of domestic substitution of the wave is accelerating, and even towards FIC (first-in-class) stride, and the high barriers and innovation of "hard technology" are constantly improving the long-term vitality and development space
of China's medical industry technology.
In this context, the field of biomedicine and medical devices injected with "hard technology" genes will naturally receive more and more attention from capital
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
